Abstract
In cancer chemotherapy, it is necessary to design an agent that suppresses or inhibits the targets that influence cell growth and apoptosis. We focus on the apoptotic pathway via mitochondria in this article. In this pathway, c-Jun N-terminal kinase (JNK), one of the stress activated protein kinases, is predominantly activated by apoptotic stimuli. JNK activity is inhibited by the binding of glutathione S-transferase P1-1 (GST P1-1) through protein-protein interactions. It has been noted that GST P1-1 overexpression plays an important role in carcinogenesis and in part in the MDR phenotype. We show several useful modifications of an anticancer agent that suppress the enzyme activity and expression of GST P1-1. The release of cytochrome c from mitochondria to the cytosol during apoptosis is mediated by the mitochondrial permeability transition pore, which is a protein complex formed by the voltage-dependent anion channel, members of the pro- and anti- apoptotic Bax-Bcl-2 protein family, cyclophilin D, and adenine nucleotide (ADP / ATP) translocators. We propose some drugs, including a proteasome inhibitor that can triger the permeability transition.
Keywords: Chemotherapeutic, proteasome, adenine nucleotide, cyclophilin D
Current Cancer Drug Targets
Title: Chemotherapeutic Agents That Induce Mitochondrial Apoptosis
Volume: 4 Issue: 7
Author(s): Tadashi Asakura and Kiyoshi Ohkawa
Affiliation:
Keywords: Chemotherapeutic, proteasome, adenine nucleotide, cyclophilin D
Abstract: In cancer chemotherapy, it is necessary to design an agent that suppresses or inhibits the targets that influence cell growth and apoptosis. We focus on the apoptotic pathway via mitochondria in this article. In this pathway, c-Jun N-terminal kinase (JNK), one of the stress activated protein kinases, is predominantly activated by apoptotic stimuli. JNK activity is inhibited by the binding of glutathione S-transferase P1-1 (GST P1-1) through protein-protein interactions. It has been noted that GST P1-1 overexpression plays an important role in carcinogenesis and in part in the MDR phenotype. We show several useful modifications of an anticancer agent that suppress the enzyme activity and expression of GST P1-1. The release of cytochrome c from mitochondria to the cytosol during apoptosis is mediated by the mitochondrial permeability transition pore, which is a protein complex formed by the voltage-dependent anion channel, members of the pro- and anti- apoptotic Bax-Bcl-2 protein family, cyclophilin D, and adenine nucleotide (ADP / ATP) translocators. We propose some drugs, including a proteasome inhibitor that can triger the permeability transition.
Export Options
About this article
Cite this article as:
Asakura Tadashi and Ohkawa Kiyoshi, Chemotherapeutic Agents That Induce Mitochondrial Apoptosis, Current Cancer Drug Targets 2004; 4 (7) . https://dx.doi.org/10.2174/1568009043332772
DOI https://dx.doi.org/10.2174/1568009043332772 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Using Cytokines to Treat Cervical Intraepithelial and Invasive Neoplasia
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Fluorescence Resonance Energy Transfer Approaches as a Tool to Quantify the Stability of Antisense Oligodeoxynucleotides
Current Pharmaceutical Analysis Application of Bioinformatics for the Search of Novel Anti-Viral Therapies: Rational Design of Anti-Herpes Agents
Current Bioinformatics Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry In Vivo Cellular Imaging for Translational Medical Research
Current Medical Imaging Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry The Role of Autophagy: What can be Learned from the Genetic Forms of Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Current Medicinal Chemistry Anticancer Activity of the Ascidian Polyclinum Indicum against Cervical Cancer Cells (HeLa) Mediated through Apoptosis Induction
Medicinal Chemistry The Role of Pericytes in Blood-Brain Barrier Function and Stroke
Current Pharmaceutical Design